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Abstract
Erythropoiesis-stimulating agents are first choice for treating anemia in low-risk MDS. This double-blind, placebo-controlled
study assessed the efficacy and safety of epoetin-α in IPSS low- or intermediate-1 risk (i.e., low-risk) MDS patients with
Hb ≤ 10.0 g/dL, with no or moderate RBC transfusion dependence (≤4 RBC units/8 weeks). Patients were randomized, 2:1,
to receive epoetin-α 450 IU/kg/week or placebo for 24 weeks, followed by treatment extension in responders. The primary
endpoint was erythroid response (ER) through Week 24. Dose adjustments were driven by weekly Hb-levels and included
increases, and dose reductions/discontinuation if Hb > 12 g/dL. An independent Response Review Committee (RRC) blindly
reviewed all responses, applying IWG-2006 criteria but also considering dose adjustments, drug interruptions and longer
periods of observation.
A total of 130 patients were randomized (85 to epoetin-α and 45 to placebo). The ER by IWG-2006 criteria was 31.8% for
epoetin-α vs 4.4% for placebo (p < 0.001); after RRC review, the ER was 45.9 vs 4.4% (p < 0.001), respectively. Epoetin-α
reduced RBC transfusions and increased the time-to-first-transfusion compared with placebo.
Thus, epoetin-α significantly improved anemia outcomes in low-risk MDS. IWG-2006 criteria for ER may require
amendments to better apply to clinical studies.
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Key points (short bulleted statements of
relevant outcomes)
● Epoetin-α improved erythroid response, reduced the
percentage of patients requiring red blood cell transfu-
sion and increased the time-to-first-transfusion com-
pared with placebo
● Epoetin-α was well tolerated in anemic patients with
low- and intermediate-1 risk MDS
Introduction
MDS are clonal myeloid disorders, characterized by ineffec-
tive hematopoiesis, leading to peripheral blood cytopenias and
an increased risk of progression to acute myeloid leukemia
(AML) [1]. Myelodysplastic syndromes (MDS) are classified
prognostically by the International Prognostic Scoring System
(IPSS). In low-risk MDS (i.e., IPSS low- or intermediate-1-
risk), anemia is the predominant feature, leading to red blood
cell (RBC) transfusion requirement, poor quality of life
(QoL), and worsening of comorbidities [2].
Until recently, lenalidomide was the only drug approved in
the EU to treat anemia associated with low-risk MDS,
but only in patients with 5q deletion; however, many
studies have evaluated erythropoiesis-stimulating agents
(ESAs) in all subgroups of patients with MDS [3–5].
Recombinant human erythropoietin alfa (epoetin-α; Eprex®)
stimulates proliferation of RBC precursors and inhibits
their apoptosis in MDS [6]. In the EU, epoetin-α is
indicated to treat symptomatic anemia associated with chronic
renal failure, chemotherapy-treated adult cancer patients at
risk of transfusion, adults in a pre-donation program to
increase the yield of autologous blood, and patients prior to
orthopedic surgery at risk of transfusion complications [7].
Epoetin-α has been used to treat anemia in low-risk MDS
patients, primarily in non-randomized, single-arm studies
[8–11]. A well-designed, randomized, double-blind study
with sufficient size and duration was required to compare
epoetin-α with placebo in improving anemia outcomes in
patients with low-risk MDS.
We designed a phase 3 multicenter double-blind placebo-
controlled study to evaluate epoetin-α as treatment for
anemia in low-risk MDS. Evaluation of our results led us to
reconsider some of the International Working group (IWG)-
2006 criteria for erythroid response (ER).
Methods
Study design
Adults with MDS were randomized in a 2:1 ratio to receive
either epoetin-α or placebo, at 29 sites in six countries across
Europe. Inclusion criteria were de novo MDS according to
WHO classification, and IPSS low- or intermediate-1 (low-
risk) at screening, hemoglobin (Hb) ≤10 g/dL (10.5 g/dL in
case of preceding transfusion), serum erythropoietin <500
mU/mL, transfusion requirement ≤4 RBC units/8 weeks,
ECOG performance status ≤2, and adequate iron, B12 and
folate levels. Exclusion criteria were therapy-related MDS,
uncontrolled hypertension, prior treatment with any ESA or
interventional agents, and a history of pure red cell aplasia.
Randomization was stratified according to transfusion
requirement (yes vs no) and serum erythropoietin levels
(≥200mU/mL vs <200mU/mL).
Epoetin-α was administered weekly, subcutaneously at
an initial dose of 450 IU/kg (up to 40,000 IU total dose) or
matching volume of placebo. Hb was measured weekly,
either centrally or at local sites. At week 8 the dose could be
increased up to 1050 IU/kg (up to 80,000 IU total dose) or
matching volume of placebo in patients not achieving an
ER. If Hb levels increased to >12 g/dL, or there was a rapid
increase in Hb levels (>2 g/dL over any 4-week period),
treatment with epoetin-α was interrupted. Stepwise dose
adjustments were permitted for patients not achieving ER,
and dose reduction/interruption driven by weekly Hb
regardless of ER status (Table S1). At the end of Week 24,
responders could enter the double-blind extension phase
through Week 48 continuing with the same dosing rules
(Figure S1). Patients completing or discontinuing treatment
were followed for a further 4 weeks.
Endpoints
The primary endpoint was ER through Week 24, according
to IWG-2006 criteria [12]. Following difficulties in asses-
sing response using the IWG-2006 criteria—due in parti-
cular to the per label dose adjustment of epoetin-α—an
independent response review committee (RRC) reviewed
blinded data on dosing, transfusions, Hb levels and some-
what modified IWG-2006 criteria for ER as follows:
(i) patients with an increase in Hb level by at least 1.5 g/dL
lasting less than 8 weeks due to epoetin-α discontinuation
were considered responders if, when restarting epoetin-α at
lower dose, Hb still increased by at least 1.5 g/dL, (ii) in
transfused patients, the baseline Hb value was taken before
the last transfusion preceding enrollment (rather than after),
and (iii) if discrepancies were observed between local and
centralized Hb levels, the latter should be used to evaluate
response and its duration (Table S2).
Secondary endpoints included duration of ER through
48 weeks, time-to-RBC-transfusion, the number of RBC
units transfused, and QoL. QoL questionnaires included the
Functional Assessment of Cancer Therapy-Anemia/Fatigue
(FACT-An), EuroQol 5-dimension (EQ-5D-3L). AEs were
collected for patients who received ≥1 dose of study
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medication. An independent data and safety monitoring
committee reviewed unblinded safety and efficacy data.
Open-label access study
Patients in Bulgaria, Greece, and Germany responding to
treatment with epoetin-α at Week 48, and non-responders
by Week 24 treated with placebo were eligible for an open-
label study, where they could receive, or continue to
receive, epoetin-α at the end of their participation in the
EPOANE3021 study. The duration was 6 months in Ger-
many and Greece, and up to 1 year after the last patient had
enrolled in Bulgaria, or until early discontinuation). Patients
were given an initial dose of epoetin-α 450 IU/kg and a
maximum dose of 40,000 IU/kg weekly for the first
8 weeks, after which the protocol-defined dosing schedule
and modifications were applied, or continued the same dose
when entering the open-label study. Patients were with-
drawn from the study when treated with the maximum dose
for 8 weeks without response.
Statistical analysis
Sample size was based on an expected response rate of 35%
and 10% in the epoetin-α and placebo groups, respectively.
Using a Fisher exact test with a 0.05 two-sided significance
level, corrected for a 10% drop out rate, ≥125 patients (83
epoetin-α, 42 placebo) were required to achieve ≥80% power.
All statistical tests were two-sided at a significance level of
0.05. Modified intent to treat (mITT—patients with ≥1 dose
and one post-baseline assessment) and per protocol (PP—no
major protocol deviations during the first 24 weeks) analyses
were used for all efficacy analyses. For ER, Fisher’s, and
Cochran–Mantel–Haenszel test were used (the latter taking
into account stratification factors and IPSS risk category at
screening). Between-group comparisons were tested using the
Fisher exact test or Wilcoxon two-sample test.
Results
Patient characteristics
Of 130 patients randomized between September 2011 and
January 2014, 85 were assigned to epoetin-α and 45 to
placebo. Baseline patient clinical characteristics were well
balanced. The median age was 75 years, and 54.6% of
patients were men (Table 1 and Table S3). Overall, 50% of
patients had an ECOG score of 1.
After 24 weeks, 24.4% in the placebo group and 17.6%
in the epoetin-α group had discontinued treatment (Fig. 1).
The most common reasons for discontinuation were AEs (in
7.1% of the patients in the epoetin-α group vs 13.3% of







Age (years), median 75 85 75
Range (years) 36–87 40–94 36–94
Sex
Male 25 (55.6%) 46 (54.1%) 71 (54.6%)
Female 20 (44.4%) 39 (45.9%) 59 (45.4%)



















Transfusions in 8 weeks prior to baseline visit
Patients with
transfusions (%)
22 (48.9%) 44 (51.8%)
No. of transfusion events
prior to baseline
36 75
Total RBC units prior to
visit
53 114




MDS subtype according to
WHO classification
n= 44 n= 82 N= 126
RA 11 (24.4%) 7 (8.2%) 18 (13.8%)
RARS 2 (4.4%) 9 (10.6%) 11 (8.5%)
RCMD 21 (46.7%) 36 (42.4%) 57 (43.8%)
RCMD-RS 5 (11.1%) 12 (14.1%) 17 (13.1%)
RAEB-1 1 (2.2%) 10 (11.8%) 11 (8.5%)
RAEB-2 0 1 (1.2%) 1 (0.8%)
MDS-U 0 1 (1.2%) 1 (0.8%)
5q- 3 (6.7%) 2 (2.4%) 5 (3.8%)
AML 0 0 0
Not available 1 (2.2%) 4 (4.7%) 5 (3.8%)
MDS subtype according to
FAB classificationa
n= 44 n= 82 N= 126
RA 35 (77.8%) 46 (54.1%) 81 (62.3%)
RARS 7 (15.6%) 21 (24.7%) 28 (21.5%)
RAEB 1 (2.2%) 11 (12.9%) 12 (9.2%)
RAEB-t 0 0 0
CMML 1 (2.2%) 4 (4.7%) 5 (3.8%)
AML 0 0 0
Not available 0 0 0
IPSS risk categoryb n= 45 n= 85 N= 130
Low 23 (51.1%) 35 (41.2%) 58 (44.6%)
Intermediate-1 (0.5–1.0) 22 (48.9%) 49 (57.6%) 71 (54.6%)
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those in the placebo group) and consent withdrawal (in 4.7
vs 6.7%) (Table S4).
Thirty-nine patients in the epoetin-α group and one
patient in the placebo group entered the 24-week extension
phase. The most common reasons for treatment dis-
continuation at any time during the 24-week extension
phase were no response to treatment and AEs (Table S4).
The median weekly dose delivered was 730.4 IU/kg
(range: 343–946) in the epoetin-α vs 850.0 IU/kg (range:
404–910) in the placebo groups. The epoetin-α dose was
decreased in 54.1% receiving the drug versus 20.0% in
those receiving placebo. The mean treatment duration for
the epoetin-α group was 30.9 (standard deviation (SD)
14.04) weeks and 21.3 (SD 6.38) weeks for the placebo
group (mITT).
Efficacy results
ER based on strict IWG 2006 response criteria
The ER was 31.8% for the epoetin-α group vs 4.4% for
the placebo group, (P<0.001; mITT) Table 2). All
responders had a serum erythropoietin level of <200 mU/
mL at baseline. In patients with no transfusion need, ER
was 50% for epoetin-α vs 4.8% for placebo. In IPSS low-
risk patients, ER was 45.7% in the epoetin-α vs 8.7% in the
placebo group; in IPSS intermediate-1 20.4 vs 0%,
respectively.
ER based on the modified-IWG-2006 response criteria
Difficulties in interpretation of IWG-2006 criteria occurred
(Table S5). First, patients who transiently discontinued
epoetin-α due to Hb>12 g/dL or received a dose reduction
following an increase of >2 g/dL in Hb over any 4-week
period often did not meet IWG-2006 criteria, as their
response was <8 weeks (due to drug discontinuation/dose
reduction). Also, because transfused patients had, as per
inclusion criteria, a RBC rate below 4 units/8 weeks, IWG-
2006 criteria required both RBC-transfusion independence
and an increase in Hb level by ≥1.5 g/dL. In addition,
baseline Hb level is defined in IWG-2006 criteria as
“average of ≥2 measurements (not influenced by transfu-
sions), 1 week apart”. However, in a patient with low-
transfusion requirement (e.g., every 6 weeks), baseline Hb
levels are not the same in the 2 weeks before and the
2 weeks after transfusions. Also, some epoetin-α dose
adjustments were based on local Hb levels (frequently
measured with a portable photometer), which sometimes
differed from Hb levels measured at the centralized
laboratory. Finally, the baseline RBC-transfusion rate
evaluated during the prior 8 weeks often did not reflect
the actual long-term RBC-transfusion rate, which was
more accurately captured by analyzing the prior 16 weeks
rate.
Taking into account these considerations, the RRC
blindly reviewed all cases, based on modified IWG
2006 response assessment. Using these criteria, the pro-
portion of ER in the first 24 weeks was 45.9% in
the epoetin-α treatment group vs 4.4% in the placebo group
(P < 0.001).
Other outcomes
Of the 27 responders, five patients discontinued treatment
before week 48 while still in response (median duration
25 weeks, range 13–38). Nine patients were still responding
at study end with a median duration of 40 weeks
(range 24–46). The remaining 13 patients had relapsed
while still on treatment, after a median of 19 weeks (range
8–44). Thus, the mean response duration in responders was
27.5 weeks, while the estimated median Kaplan–Meier
estimated duration of response was 44 weeks.
Figure 2 shows the time-to-first-RBC-transfusion








Intermediate-2 (1.5–2.0) 0 0 0
High (≥2.5) 0 0 0
Missing 0 1 (1.2%) 1 (0.8%)
P value 0.355
ECOG score n= 45 n= 85 N= 130
0—fully active 20 (44.4%) 35(41.2%) 55 (42.3%)
1—restricted but ambulatory 23 (51.1%) 42 (49.4%) 65 (50.0%)
2—ambulatory 2 (4.4%) 8 (9.4%) 10 (7.7%)
3—capable but confined to
bed/chair
0 0 0
4—completely disabled 0 0 0
5q- myelodysplastic syndromes associated with isolated del(5q),
AML acute myeloid leukemia, CMML chronic myelomonocytic
leukemia, FAB French-American-British, IPSS International Prog-
nostic Scoring System, ECOG Eastern Cooperative Oncology Group,
MDSmyelodysplastic syndromes, MDS-U myelodysplastic syn-
drome, unclassified, RA refractory anemia, RARS refractory anemia
with ringed sideroblasts, RAEB refractory anemia with excess blasts,
RAEB-t refractory anemia with excess blasts in transformation, RBC
red blood cells, RCMD refractory cytopenia with multilineage
dysplasia, RCMD-RS refractory cytopenia with multilineage dysplasia
with ringed sideroblasts, SD standard deviation, WHOWorld Health
Organization
aAccording to FAB, CMML patients were marked as MDS subtype
not available in the WHO classification
bOne patient was missing the IPSS category at screening. The pvalue
for treatment group differences are based on the Fisher exact test, two-
sided
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Fig. 1 CONSORT flow diagram
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was a significant difference in time-to-first-transfusion in
the epoetin-α group vs placebo group (log-rank test: median
7.0 vs 5.3 weeks, respectively P= 0.046; hazard ratio [HR]
1.653 (95% confidence interval [CI] 0.999–2.736). The
separation between the two treatment groups began around
Week 4: the difference in RBC transfusions occurring after
Week 4 was a median 20.3 weeks (95% CI, 7.7–39.6) in the
epoetin-α, and 7.1 weeks (95% CI 6.1–9.6) in the placebo
groups (P= 0.007) (Fig. 3).
Between baseline and Week 24, 36 (42.4%) patients in
the epoetin-α group received 163 transfusions (total RBC
units= 266; units per patients= 7.4); and 26 (57.8%)
patients in the placebo group received 125 transfusions
(total RBC units= 196; units per subject= 7.5).
At Week 24, the mean increase from baseline in the
Hb levels in the epoetin-α group was 1.04 g/dL and the
mean decrease in the Hb levels in the placebo group was
0.07 g/dL (Table S7).
Table 2 Erythroid response at any time during the first 24 weeks (mITT and PP analyses)









Patients with erythroid responsea at any time during the first 24 weeks of the study 2 (4.4%) 27 (31.8%) 0 11 (34.4%)
P valueb <0.001 0.002
Patients with erythroid response by stratification group
No transfusion and serum erythropoietin level less than 200 mU/mLc 1 (4.8%) 20 (50.0%) 0 8 (66.7%)
Transfusion and serum erythropoietin level less than 200 mU/mLc 1 (5.6%) 7 (22.6%) 0 3 (25.0%)
No transfusion and serum erythropoietin level at least 200 mU/mL 0 0 0 0
Transfusion and serum erythropoietin level at least 200 mU/mL 0 0 0 0
P valued <0.001 0.001
Patients with erythroid response by IPSS risk category
Low= 0e 2 (8.7%) 16 (45.7%) 0 7 (58.3%)
Intermediate-1= 0.5–1.0e 0 10 (20.4%) 0 4 (20.0%)
Intermediate-2= 1.5–2.0 0 0 0 0
High= ≥ 2.5 0 0 0 0
No IPSS at screening 0 1 0 0
P valued <0.001 0.001
Percentage of patients with erythroid response at any time during the
first 24 weeks of study for evaluable patientsf
2 (4.4%) 27 (32.9%) 0 11 (34.3%)
High Intermediate Low
ER according to Nordic Score Classification
Responders 21 (44.7%) 6 (16.7%)
Nonresponders 26 (55.3%) 30 (83.3%) 1 (100%)
MDS subtypes RA/RCMD RARS/RCMD-RS
ER according to RA/RCMD and RARS/RCMD-RS MDS subtypes
Responders 13 (30.2%) 8 (38.1%)
Nonresponders 30 (69.8%) 13 (61.9%)
CMH Cochran–Mantel–Haenszel, IPSS International Prognostic Scoring Systems, IWG International Working Group, NR not reported; RBC
red blood cell, RRC Response Review Committee
aErythroid response assessed according to the IWG 2006 criteria: Hemoglobin increase by ≥1.5 g/dL or relevant reduction of RBC units transfused
by an absolute number of at least four units every 8 weeks compared with the pretreatment transfusion number in the previous 8 weeks; responses
must last at least 8 weeks
bP value for treatment group differences are based on the Fisher exact test, two-sided
cmITT analysis: The CMH p-value and percentages are based on the number of patients in that strata: placebo, Strata 1= 20 and Strata 2= 19;
epoetin alfa, Strata 1= 38 and Strata 2= 33; PP analysis: placebo, Strata 1= 8 and Strata 2= 10; epoetin alfa, Strata 1= 12 and Strata 2= 12
dP value for treatment group differences are based on the CMH test, two-sided
eThe CMH P value and percentages are based on the number of patients in that IPSS category: placebo, low 0= 23 and intermediate-1= 22;
epoetin-α, low 0= 35 and intermediate-1= 49
fThe denominator excludes patients who were determined by the RRC as not evaluable
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QoL
There were no significant differences in QoL between the
epoetin-α group and the placebo at any time point. QoL at
Week 24 was significantly different between the responders
in the epoetin-α group and the placebo group (EQ-5D index
score P= 0.034).
Safety results
During the 24 weeks of the randomized study (Tables 3 and
4), more patients in the placebo group (88.9%) reported one
or more TEAE compared with the epoetin-α group (77.6%).
At least one TEAE leading to permanent discontinuation of
study treatment was reported in 10.6% of patients in the
epoetin-α group and 13.3% of patients in the placebo group
(Table 5). Similar numbers of patients reported at least one
TEAE of toxicity grade 3 or grade 4 in the epoetin-α and
placebo groups (25.9 vs 26.7%).
Treatment-emergent severe adverse events (SAE) were
reported by 25.9% and 17.8% of patients in the epoetin-α
and placebo groups, respectively. Two treatment-emergent
SAEs in the epoetin-α group were considered related to
study drug by the investigator: thromboembolism (distal
deep venous thrombosis, during the first 24 weeks of
treatment) and in one patient the anti-erythropoietin anti-
body testing (after 24 weeks of treatment) was positive
during the routine study safety assessment, which led to
permanent discontinuation of the study drug. There were no
signs of pure red cell aplasia in the patient’s bone marrow
and serum erythropoietin remained detectable and reticu-
locytes were normal at the last available measurement.
No SAE reported in the placebo group was considered by
the investigator to be related to the study agent.
AEs that occurred at a frequency of 2% or more in the
epoetin-α group or the placebo group were asthenia (14.1 vs
11.1%), fatigue (9.4 vs 2.2%), nasopharyngitis (7.1 vs
4.4%), diarrhea and dyspnea (9.4 vs 2.2%), constipation
(7.1% vs 0), and pruritus (5.9% vs 0).
Thrombovascular events were reported in four patients in
the epoetin-α group and none of the patients in the placebo
group. Three of the events were confirmed as ischemic
stroke, embolism, and phlebitis, and the study investigator
considered one embolism to be related to the study agent.
Two patients had significant risk factors for thrombovas-
cular events including a medical history or ischemic stroke,
atrial fibrillation, congestive heart failure, and superficial
thrombophlebitis. No further thrombovascular events were
reported in the study after Week 24.
Also, during the first 24 weeks, 11 patients in the
epoetin-α group (12.9%), and 4 patients in the placebo
group (8.9%) experienced disease progression, including 53
[3.5%] AML progressions in the epoetin-α group and 2
[4.4%] in the placebo group. All progressions to AML
occurred prior to or at Week 24. After Week 24, three
additional patients in the epoetin-α group experienced dis-
ease progression (one at Week 44 and two at Week 48)
(Table S6).
Fig. 2 Time-to-first-red blood cell (RBC)-transfusions (mITT)
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Five deaths occurred due to TEAE with onset during
the first 24 weeks of the study: four in the epoetin-α group
(due to AML, sudden death, cachexia, and renal failure) and
one in the placebo group (due to AML). None of the deaths
was considered by the investigators to be related to study
agent.
Open-label access study: efficacy and safety
Twenty-six patients enrolled in the open-label access study
(Table S8), including 10 non-responders in the placebo
group after week 24, (7 of whom responded to treatment),
and 16 patients responders enrolled after 48 weeks to con-
tinue treatment (13 did not relapse) (Table S9).
Discussion
This is the first placebo-controlled, randomized study
assessing epoetin-α (without possible addition of G-CSF) in
anemia associated with IPSS low- or intermediate-1-risk
MDS. Epoetin-α significantly induced and sustained ER
(assessed using IWG-2006 criteria), significantly reduced
the RBC transfusion requirements, and prolonged the time-
to-first-RBC-transfusion.
ER with epoetin-α was 31.8% strictly applying IWG-
2006 criteria, i.e., lower than ER generally reported in phase
II trials with epoetin-α at similar dosing schedules in low-
and intermediate-1-risk MDS patients [13–17]. In a study
by Greenberg et al. also applying strictly IWG 2006 criteria,
the ER rate with erythropoietin alone was 34% [13]. On the
other hand, in our study, the ER increased to 45.9% after
blindly reviewing responses and adjusting response criteria.
Application of IWG-2006 criteria was affected by patients
who had to transiently discontinue epoetin-α due to a rapid
rise in Hb level, and therefore, often had responses shorter
than 8 weeks (due to drug discontinuation). Additionally,
because only moderately transfused patients could be
included, not only RBC transfusion independence, but also
an increase in Hb level >1.5 g/dL was required, raising the
problem of what baseline Hb level should be chosen in
regularly transfused patients. Other difficulties were the
differences in values recorded when Hb levels were asses-
sed at local centers compared with centralized assessments.
For those reasons, a RRC blindly reviewed all cases, based
on modifications of IWG-2006 criteria that took into
account drug discontinuations due to “over” response,
choosing a pre-transfusion baseline level in transfusion
dependent patients, and relying only on a centralized Hb
level in case of discrepancies with local Hb level.
After this review, the ER increased from 31.8 to 45.9%
in the epoetin-α group and remained at 4.4% in the placebo
group. Similar increases in ER after review of IWG 2006
criteria were observed in a recent study of darbepoetin [18].
The results of the open-label access study further support
this interpretation, as patients who began treatment with
epoetin-α during this phase of the study, had an ER rate of
50% using IWG-2006 criteria.
In this study, ER was not significantly different in the
RARS/RCMD-RS vs RA/RCMD MDS subtypes (38.1 vs
Fig. 3 Time-to-first-red blood cell (RBC)-transfusions after week 4 by RRC responder status (mITT)
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30.2%). Our results were also influenced by Nordic Score
prognostic factors [19], based on baseline erythropoietin level
and RBC transfusion requirement. However, the response rates
were lower in our study than those reported by Hellström-
Lindberg et al. (e.g., High Nordic Score: 44.7 vs 74%).
The mean duration of response was 27.5 weeks, and the
Kaplan–Meier analysis estimated the median duration of
response to be 44 weeks, i.e., less than median responses of
20–24 months usually reported in the literature [13–17].
However, this endpoint was difficult to assess in the present
study since many patients discontinued treatment while still
responding (including patients deemed non responders per
strict IWG 2006 criteria).
The safety findings were consistent with the known
profile of epoetin-α [4, 13–15, 20–22], or were related to
patients’ underlying health conditions.
Table 3 Treatment-emergent AEs that occurred in the first 24 weeks





General disorders 17 (37.8%) 31 (36.5%)
Asthenia 5 (11.1%) 12 (14.1%)
Fatigue 3 (6.7%) 8 (9.4%)
Pyrexia 5 (11.1%) 7 (8.2%)
Edema peripheral 5 (11.1%) 3 (3.5%)
Infections and infestations 11 (24.4%) 24 (28.2%)
Nasopharyngitis 2 (4.4%) 6 (7.1%)
Gastrointestinal disorders 8 (17.8%) 24 (28.2%)
Diarrhea 1 (2.2%) 8 (9.4%)
Constipation 0 6 (7.1%)
Metabolism and nutrition disorders 4 (8.9%) 15 (17.6%)
Respiratory, thoracic and mediastinal
disorders
4 (8.9%) 13 (15.3%)
Dyspnea 1 (2.2%) 8 (9.4%)
Skin and subcutaneous tissue disorders 4 (8.9%) 12 (14.1%)
Pruritus 0 5 (5.9%)
Musculoskeletal and connective tissue
disorders
11 (24.4%) 11 (12.9%)
Back pain 3 (6.7%) 1 (1.2%)
Investigations 7 (15.6%) 10 (11.8%)
Vascular disorders 4 (8.9%) 10 (11.8%)
Blood and lymphatic system disorders 7 (15.6%) 9 (10.6%)
Anemia 5 (11.1%) 5 (5.9%)
Injury, poisoning and procedural
complications
5 (11.1%) 8 (9.4%)
Neoplasms benign, malignant and
unspecified (including cysts and
polyps)
7 (15.6%) 6 (7.1%)
Cardiac disorders 3 (6.7%) 6 (7.1%)
Table 4 Treatment-emergent adverse events of toxicity grade 3 or 4
that occurred in the first 24 weeks of the study (safety analysis—
treatment phase only)
Placebo Epoetin-α
Infections and infestations 2 (4.4%) 5 (5.9%)
Pneumonia 2 (4.4%) 1 (1.2%)
Sinusitis 0 1 (1.2%)
Soft tissue infection 0 1 (1.2%)
Tooth abscess 0 1 (1.2%)
Urosepsis 0 1 (1.2%)
Blood and lymphatic system disorders 2 (4.4%)
1 (2.2%)
1 (1.2%)
Anemia 1 (2.2%) 1 (1.2%)
Thrombocytopenia 1 (2.2%) 1 (1.2%)
Neutropenia 0 1 (1.2%)
Gastrointestinal disorders 1 (2.2%) 3 (3.5%)
Abdominal pain 0 1 (1.2%)
Diarrhea 0 1 (1.2%)
Gastritis 0 1 (1.2%)
Ileitis 0 1 (1.2%)
Esophagitis 0 1 (1.2%)
Vomiting 0 1 (1.2%)
Toothache 1 (2.2%) 0
Vascular disorders 1 (2.2%) 2 (2.4%)
Embolism 0 1 (1.2%)
Systolic hypertension 0 1 (1.2%)
Aortic dissection 1 (1.2%) 0
Musculoskeletal and connective tissue
disorders
0 2 (2.4%)
Back pain 0 1 (1.2%)
Pain in extremity 0 1 (1.2%)
Investigations 4 (8.9%) 1 (1.2%)
Blood pressure increased 0 1 (1.2%)
Serum ferritin increased 2 (4.4%) 0
Hemoglobin decreased 1 (2.2%) 0
Lymphocyte count decreased 1 (2.2%) 0
Neutrophil count decreased 1 (2.2%) 0
White blood cell count decreased 1 (2.2%) 0
Injury, poisoning and procedural
complications
0 1 (1.2%)
Traumatic brain injury 0 1 (1.2%)
Metabolism and nutrition disorders 0 1 (1.2%)
Diabetes mellitus 0 1 (1.2%)
General disorders and administration site
conditions
2 (4.4%) 0
Disease progression 1 (2.2%) 0
Pyrexia 1 (2.2%) 0
Cardiac disorders 1 (2.2%) 0
Arrhythmia 1 (2.2%) 0
Psychiatric disorders 1 (2.2%) 0
Depression 1 (2.2%) 0
2656 P. Fenaux et al.
This study supports the efficacy and safety of epoetin-α
in patients with anemia associated with low-risk MDS.
Based on these results, the risk-benefit profile of epoetin-α
in the treatment of anemia in patients with low-risk MDS is
positive. As a result of this study, epoetin-α has been
approved by the French ANSM [23, 24].
Finally, IWG-2006 criteria were difficult to apply, as
previously experienced in the MDS 005 study of lenalido-
mide in non-deletion-5q low-risk MDS [23]. IWG criteria
for response assessment may have to be modified to be
applicable to clinical study design. Amendments to IWG-
2006 criteria could include separating RBC transfusion
dependent patients into those with low and high RBC-
transfusion dependence, defining transfusion dependence
over the previous 16 weeks (rather than eight weeks), better
defining timing of “baseline Hb level” and taking into
account treatment discontinuation due to “over” response,
defining a tolerable period (days) of oscillation of Hb with
subsequent return to previous levels that does not impact on
overall response, and the intervals of measurement of Hb
(weekly/biweekly) during treatment.
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